

## **Global Cholera Vaccines Market Report and Forecast 2023-2031**

Market Report | 2023-04-27 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Cholera Vaccines Market Report and Forecast 2023-2031

Global Cholera Vaccines Market Outlook

The global cholera vaccines market size attained a value of USD 107.7 million in 2022. The market is anticipated to grow at a CAGR of 12.0% during the forecast period of 2023-2031 to attain a value of USD 297.8 million by 2031.

#### **Cholera Vaccines Market: Introduction**

Cholera vaccines are biological preparations that provide protection against cholera, a severe diarrheal disease caused by the bacterium *Vibrio cholerae*. The disease is transmitted through contaminated water and food, and can result in rapid dehydration, severe electrolyte imbalance, and even death if left untreated. Cholera is particularly prevalent in regions with poor sanitation, inadequate water treatment, and limited access to healthcare facilities. Vaccination is an essential tool in preventing cholera outbreaks and managing the disease in endemic regions.

#### **Uses of Cholera Vaccines:**

- ☐ Preventive measure: Cholera vaccines are administered to individuals in areas where cholera is endemic, or where there is a risk of an outbreak, to prevent the spread of the disease.
- ☐ Travelers: Travelers to cholera-affected regions may be advised to receive the cholera vaccine to protect themselves from infection during their stay.
- ☐ Emergency response: Cholera vaccines can be used during humanitarian crises, such as natural disasters or refugee situations, where there is an increased risk of cholera outbreaks due to the disruption of water and sanitation systems.

#### **Benefits of Cholera Vaccines:**

1. ☐ Disease prevention: Cholera vaccines significantly reduce the risk of infection, helping to prevent illness and the spread of the disease within communities.
2. ☐ Reduced morbidity and mortality: By preventing cholera infection, the vaccines help decrease the number of severe cases and fatalities associated with the disease.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

3. Cost-effectiveness: Cholera vaccination campaigns can be more cost-effective than treating individual cases of the disease, as they help prevent the need for expensive medical interventions, such as intravenous rehydration therapy and hospitalization.
4. Strengthening public health efforts: Cholera vaccines are an important component of comprehensive public health strategies to control the disease, which also includes improving water and sanitation systems and promoting hygiene practices.
5. Support for healthcare systems: By reducing the number of cholera cases, vaccines can help ease the burden on healthcare systems in affected regions, allowing them to allocate resources more effectively.

There are currently several cholera vaccines available, including oral vaccines like Dukoral, Shanchol, and Euvichol. These vaccines typically require multiple doses to provide optimal protection, and the immunity they confer may decrease over time, necessitating periodic booster doses. It is important to note that while cholera vaccines are highly beneficial, they should not replace efforts to improve water and sanitation infrastructure, as well as promote proper hygiene practices to control the disease in the long term.

#### cholera Vaccines Market Segmentations

The market can be categorised into product, end user, and region.

##### Cholera Vaccines Market Breakup by Product

- Dukoral
- Shanchol
- Vaxchora
- Euvichol
- Others

##### Cholera Vaccines Market Breakup by End User

- Hospitals & Clinics
- Research and Academic Laboratories
- Others

##### Cholera Vaccines Market Breakup by Region

- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

## Cholera Vaccines Market Scenario

The cholera vaccines market has been experiencing steady growth, driven by several factors that contribute to the increasing demand for effective prevention measures against cholera. The market is primarily influenced by the prevalence of cholera in regions with poor sanitation, inadequate water treatment, and limited access to healthcare facilities, which increases the need for vaccination campaigns.

-□One of the primary drivers of the cholera vaccines market is the increased focus on public health initiatives by governments, non-governmental organizations, and international agencies such as the World Health Organization (WHO). These organizations have been actively engaged in implementing cholera vaccination programs in regions where the disease is endemic or at risk of outbreaks. This has led to a higher demand for cholera vaccines, as well as increased funding for their development and distribution.

-□Another factor contributing to the growth of the cholera vaccines market is the rise in global travel, which exposes more individuals to cholera-affected regions. As a result, the demand for cholera vaccines among travellers has increased, leading to a wider distribution of the vaccines in travel clinics and other healthcare facilities.

-□Climate change and its effects on weather patterns have also contributed to the increasing incidence of cholera outbreaks in some regions. Flooding, for example, can disrupt water and sanitation systems, leading to the contamination of water supplies and the spread of cholera. This has heightened the need for effective cholera vaccines to protect vulnerable populations and prevent the spread of the disease.

-□The cholera vaccines market is segmented based on product types (such as Dukoral, Shanchol, and Euvichol), distribution channels (public healthcare providers, private healthcare providers, and travel clinics), and geographical regions (North America, Europe, Asia-Pacific, and the rest of the world). The Asia-Pacific region, in particular, has been a significant market for cholera vaccines, given the higher prevalence of the disease in certain countries within the region.

-□The market is characterized by the presence of several key players, including both established pharmaceutical companies and emerging biotechnology firms, involved in the development, manufacturing, and distribution of cholera vaccines. As the demand for effective cholera vaccines continues to grow, these companies are likely to invest in research and development to improve existing vaccines and create new, more effective products.

In conclusion, the cholera vaccines market is expected to maintain its growth trajectory in the coming years, driven by increased public health initiatives, global travel, and the ongoing need to prevent and control cholera outbreaks worldwide.

## Key Players in the Global Cholera Vaccines Market

The report gives an in-depth analysis of the key players involved in the cholera vaccines market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Sanofi-aventis Groupe
- Emergent BioSolutions Inc.
- Valneva SE
- GlaxoSmithKline plc.
- Intervet Inc.
- EuBiologics Co., Ltd.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- [ ] Astellas Pharma Inc.
- [ ] Celldex Therapeutics.
- [ ] Johnson & Johnson Services Inc.
- [ ] Merck & Co. Inc.

## Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
  - 1.4 Research Methodology
- 2 Executive Summary
- 3 Cholera Overview
  - 3.1 Guidelines and Stages
  - 3.2 Pathophysiology
  - 3.3 Screening and Diagnosis
  - 3.4 Treatment Pathway
- 4 Patient Profile
  - 4.1 Patient Profile Overview
  - 4.2 Patient Psychology and Emotional Impact Factors
  - 4.3 Risk Assessment and Treatment Success Rate
- 5 Cholera Vaccine Epidemiology Analysis
  - 5.1 Epidemiology Overview (2016-2031)
  - 5.2 North America Cholera Epidemiology (2016-2031)
  - 5.3 Europe Cholera Epidemiology (2016-2031)
  - 5.4 Asia-Pacific Cholera Epidemiology (2016-2031)
  - 5.5 Latin America Cholera Epidemiology (2016-2031)
  - 5.6 Middle East & Africa Cholera Epidemiology (2016-2031)
- 6 Global Cholera Vaccine Market Overview
  - 6.1 Global Cholera Vaccine Market Historical Value (2016-2022)
  - 6.2 Global Cholera Vaccine Market Forecast Value (2023-2031)
- 7 Global Cholera Vaccine Market Landscape
  - 7.1 Cholera Vaccine: Developers Landscape
    - 7.1.1 Analysis by Year of Establishment
    - 7.1.2 Analysis by Company Size
    - 7.1.3 Analysis by Region
  - 7.2 Cholera Vaccine: Product Landscape
    - 7.2.1 Analysis by Product
    - 7.2.2 Analysis by End User
- 8 Cholera Vaccine Challenges and Unmet Needs
  - 8.1 Treatment Pathway Challenges
  - 8.2 Compliance and Drop-Out Analysis
  - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10 Global Cholera Vaccine Market Dynamics
  - 10.1 Market Drivers and Constraints
  - 10.2 SWOT Analysis
  - 10.3 Porter's Five Forces Model
  - 10.4 Key Demand Indicators
  - 10.5 Key Price Indicators
  - 10.6 Industry Events, Initiatives, and Trends
  - 10.7 Value Chain Analysis
- 11 Global Cholera Vaccine Market Segmentation
  - 11.1 Global Cholera Vaccine Market by Product
    - 11.1.1 Market Overview
    - 11.1.2 Dukoral
    - 11.1.3 Shanchol
    - 11.1.4 Vaxchora
    - 11.1.5 Euvichol
    - 11.1.6 Others
  - 11.2 Global Cholera Vaccine Market by End User
    - 11.2.1 Market Overview
    - 11.2.2 Hospitals & Clinics
    - 11.2.3 Research and Academic Laboratories
    - 11.2.4 Others
  - 11.3 Global Cholera Vaccine Market by Region
    - 11.3.1 Market Overview
    - 11.3.2 North America
    - 11.3.3 Europe
    - 11.3.4 Asia Pacific
    - 11.3.5 Latin America
    - 11.3.6 Middle East and Africa
- 12 North America Cholera Vaccine Market
  - 12.1 Market Share by Country
  - 12.2 United States of America
  - 12.3 Canada
- 13 Europe Cholera Vaccine Market
  - 13.1 Market Share by Country
  - 13.2 United Kingdom
  - 13.3 Germany
  - 13.4 France
  - 13.5 Italy
  - 13.6 Others
- 14 Asia Pacific Cholera Vaccine Market
  - 14.1 Market Share by Country
  - 14.2 China
  - 14.3 Japan
  - 14.4 India
  - 14.5 ASEAN
  - 14.6 Australia
  - 14.7 Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15 Latin America Cholera Vaccine Market
  - 15.1 Market Share by Country
  - 15.2 Brazil
  - 15.3 Argentina
  - 15.4 Mexico
  - 15.5 Others
- 16 Middle East and Africa Cholera Vaccine Market
  - 16.1 Market Share by Country
  - 16.2 Saudi Arabia
  - 16.3 United Arab Emirates
  - 16.4 Nigeria
  - 16.5 South Africa
  - 16.6 Others
- 17 Regulatory Framework
  - 17.1 Regulatory Overview
    - 17.1.1 US FDA
    - 17.1.2 EU EMA
    - 17.1.3 INDIA CDSCO
    - 17.1.4 JAPAN PMDA
    - 17.1.5 Others
- 18 Patent Analysis
  - 18.1 Analysis by Type of Patent
  - 18.2 Analysis by Publication year
  - 18.3 Analysis by Issuing Authority
  - 18.4 Analysis by Patent Age
  - 18.5 Analysis by CPC Analysis
  - 18.6 Analysis by Patent Valuation
  - 18.7 Analysis by Key Players
- 19 Grants Analysis
  - 19.1 Analysis by year
  - 19.2 Analysis by Amount Awarded
  - 19.3 Analysis by Issuing Authority
  - 19.4 Analysis by Grant Application
  - 19.5 Analysis by Funding Institute
  - 19.6 Analysis by NIH Departments
  - 19.7 Analysis by Recipient Organization
- 20 Clinical Trials Analysis
  - 20.1 Analysis by Trial Registration Year
  - 20.2 Analysis by Trial Status
  - 20.3 Analysis by Trial Phase
  - 20.4 Analysis by Therapeutic Area
  - 20.5 Analysis by Geography
- 21 Funding and Investment Analysis
  - 21.1 Analysis by Funding Instances
  - 21.2 Analysis by Type of Funding
  - 21.3 Analysis by Funding Amount
  - 21.4 Analysis by Leading Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Partnership and Collaborations Analysis
  - 22.1 Analysis by Partnership Instances
  - 22.2 Analysis by Type of Partnership
  - 22.3 Analysis by Leading Players
  - 22.4 Analysis by Geography
- 23 Supplier Landscape
  - 23.1 Sanofi-aventis Groupe
    - 23.1.1 Financial Analysis
    - 23.1.2 Product Portfolio
    - 23.1.3 Demographic Reach and Achievements
    - 23.1.4 Mergers and Acquisitions
    - 23.1.5 Certifications
  - 23.2 Emergent BioSolutions Inc.
    - 23.2.1 Financial Analysis
    - 23.2.2 Product Portfolio
    - 23.2.3 Demographic Reach and Achievements
    - 23.2.4 Mergers and Acquisitions
    - 23.2.5 Certifications
  - 23.3 Valneva SE
    - 23.3.1 Financial Analysis
    - 23.3.2 Product Portfolio
    - 23.3.3 Demographic Reach and Achievements
    - 23.3.4 Mergers and Acquisitions
    - 23.3.5 Certifications
  - 23.4 GlaxoSmithKline plc.
    - 23.4.1 Financial Analysis
    - 23.4.2 Product Portfolio
    - 23.4.3 Demographic Reach and Achievements
    - 23.4.4 Mergers and Acquisitions
    - 23.4.5 Certifications
  - 23.5 Intervet Inc.
    - 23.5.1 Financial Analysis
    - 23.5.2 Product Portfolio
    - 23.5.3 Demographic Reach and Achievements
    - 23.5.4 Mergers and Acquisitions
    - 23.5.5 Certifications
  - 23.6 EuBiologics Co., Ltd.
    - 23.6.1 Financial Analysis
    - 23.6.2 Product Portfolio
    - 23.6.3 Demographic Reach and Achievements
    - 23.6.4 Mergers and Acquisitions
    - 23.6.5 Certifications
  - 23.7 Astellas Pharma Inc.
    - 23.7.1 Financial Analysis
    - 23.7.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Celldex Therapeutics.
  - 23.8.1 Financial Analysis
  - 23.8.2 Product Portfolio
  - 23.8.3 Demographic Reach and Achievements
  - 23.8.4 Mergers and Acquisitions
  - 23.8.5 Certifications
- 23.9 Johnson & Johnson Services Inc.
  - 23.9.1 Financial Analysis
  - 23.9.2 Product Portfolio
  - 23.9.3 Demographic Reach and Achievements
  - 23.9.4 Mergers and Acquisitions
  - 23.9.5 Certifications
- 23.10 Merck & Co. Inc.
  - 23.10.1 Financial Analysis
  - 23.10.2 Product Portfolio
  - 23.10.3 Demographic Reach and Achievements
  - 23.10.4 Mergers and Acquisitions
  - 23.10.5 Certifications
- 24 Cholera Vaccine - Distribution Model (Additional Insight)
  - 24.1 Overview
  - 24.2 Potential Distributors
  - 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
  - 26.1 Very Small Companies
  - 26.2 Small Companies
  - 26.3 Mid-Sized Companies
  - 26.4 Large Companies
  - 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
  - 27.1 Government Funded
  - 27.2 Private Insurance
  - 27.3 Out-of-Pocket



## Global Cholera Vaccines Market Report and Forecast 2023-2031

Market Report | 2023-04-27 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com